Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Previous Page Page 2 of 19 Next Page
  1. Content type: Research article

    Expression and activity of heparanase, an endoglycosidase that cleaves heparan sulfate (HS) side chains of proteoglycans, is associated with progression and poor prognosis of many cancers which makes it an att...

    Authors: C. P. Baburajeev, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, Daniel J. Mason, Julian E. Fuchs, Andreas Bender, Uri Barash, Israel Vlodavsky, Basappa and Kanchugarakoppal S. Rangappa

    Citation: BMC Cancer 2017 17:235

    Published on:

  2. Content type: Research article

    Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract ev...

    Authors: Gerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries and Steven de Jong

    Citation: BMC Cancer 2017 17:232

    Published on:

  3. Content type: Research article

    Former studies already revealed the anti-neoplastic properties of the anti-infective agent Taurolidine (TRD) against many tumor species in vitro and in vivo. Its anti-proliferative and cell death inducing capacit...

    Authors: M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik

    Citation: BMC Cancer 2017 17:216

    Published on:

  4. Content type: Research article

    Glioblastoma multiforme (GBM) is the most common, invasive and deadly primary type of malignant brain tumor. The Phosphatidylinositol-3-Kinase/AKT (PI3K/AKT) pathway is highly active in GBM and has been associ...

    Authors: Ravi S. Narayan, Carlos A. Fedrigo, Eelke Brands, Rogier Dik, Lukas J.A. Stalpers, Brigitta G. Baumert, Ben J. Slotman, Bart A. Westerman, Godefridus J. Peters and Peter Sminia

    Citation: BMC Cancer 2017 17:204

    Published on:

  5. Content type: Research article

    Glioblastoma is the most frequent and most malignant brain tumor with the patients having a median survival of only 14.6 months. Although glioblastoma patients are treated with surgery, radiation and chemother...

    Authors: Stine S. Jensen, Stine A. Petterson, Bo Halle, Charlotte Aaberg-Jessen and Bjarne W. Kristensen

    Citation: BMC Cancer 2017 17:178

    Published on:

  6. Content type: Research article

    We previously showed that 1-methylnicotinamide (1-MNA) and its analog 1,4-dimethylpyridine (1,4-DMP) could inhibit the formation of lung metastases and enhance the efficacy of cyclophosphamide-based chemothera...

    Authors: Agnieszka Denslow, Marta Switalska, Marcin Nowak, Magdalena Maciejewska, Stefan Chlopicki, Andrzej Marcinek, Jerzy Gebicki and Joanna Wietrzyk

    Citation: BMC Cancer 2017 17:177

    Published on:

  7. Content type: Research article

    The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has ...

    Authors: Patricia M. LoRusso, Jeffrey R. Infante, Kevin B. Kim, Howard A. Burris III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson and Roger B. Cohen

    Citation: BMC Cancer 2017 17:173

    Published on:

  8. Content type: Research article

    Approximately 250 million people worldwide are chronically infected with hepatitis B virus (HBV) and more than half of the hepatocellular carcinoma (HCC) cases are attributed to this infection. As HCC has a hi...

    Authors: Jeffery Fairman, Katherine H. Liu and Stephan Menne

    Citation: BMC Cancer 2017 17:172

    Published on:

  9. Content type: Research article

    Human triple-negative breast cancer has limited therapeutic choices. Breast tumor cells have depolarized plasma membrane potential. Using this unique electrical property, we aim to develop an effective selecti...

    Authors: Han-Gang Yu, Sarah McLaughlin, Mackenzie Newman, Kathleen Brundage, Amanda Ammer, Karen Martin and James Coad

    Citation: BMC Cancer 2017 17:169

    Published on:

  10. Content type: Research article

    Neuroblastoma (NB), a tumor of the primitive neural crest, despite aggressive treatment portends a poor long-term survival for patients with advanced high stage NB. New treatment strategies are required.

    Authors: Reza Bayat Mokhtari, Narges Baluch, Micky Ka Hon Tsui, Sushil Kumar, Tina S. Homayouni, Karen Aitken, Bikul Das, Sylvain Baruchel and Herman Yeger

    Citation: BMC Cancer 2017 17:156

    Published on:

  11. Content type: Research article

    Wogonin is an encouraging choice for clinical use owing to its potent anti-tumor and anti-inflammatory effects with the high safety profile. However, wogonin for targeted therapy of lymphoma was not well addre...

    Authors: Xue Wu, Ping Liu, Haijun Zhang, Yuan Li, Jumah Masoud Mohammad Salmani, Fei Wang, Ke Yang, Rong Fu, Zhewei Chen and Baoan Chen

    Citation: BMC Cancer 2017 17:147

    Published on:

  12. Content type: Research article

    The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancre...

    Authors: Berta Laquente, Jose Lopez-Martin, Donald Richards, Gerald Illerhaus, David Z. Chang, George Kim, Philip Stella, Dirk Richel, Cezary Szcylik, Stefano Cascinu, G. L. Frassineti, Tudor Ciuleanu, Karla Hurt, Scott Hynes, Ji Lin, Aimee Bence Lin…

    Citation: BMC Cancer 2017 17:137

    Published on:

  13. Content type: Research article

    Cisplatin (DDP)-based chemotherapy is the common first-line therapy for lung cancer. However, their efficacy is often limited by primary drug resistance and/or acquired drug resistance. The aim of this study w...

    Authors: Lin Shi, Zhaozhong Xu, Gang Wu, Xiaoting Chen, Yuanyuan Huang, Yanjing Wang, Weiqiang Jiang and Bin Ke

    Citation: BMC Cancer 2017 17:138

    Published on:

  14. Content type: Research article

    Bacterial toxins have evolved to an effective therapeutic option for cancer therapy. The Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin with selective cytotoxicity. The transmembrane tight junc...

    Authors: Jessica Pahle, Lutz Menzel, Nicole Niesler, Dennis Kobelt, Jutta Aumann, Maria Rivera and Wolfgang Walther

    Citation: BMC Cancer 2017 17:129

    Published on:

  15. Content type: Research article

    Antiangiogenic therapies are considered promising for the treatment of glioblastoma (GB). The non-collagenous C-terminal globular NC1 domain of type VIII collagen a1 chain, Vastatin, is an endogenous antiangio...

    Authors: Yi Li, Jun Li, Yat Ming Woo, Zan Shen, Hong Yao, Yijun Cai, Marie Chia-mi Lin and Wai Sang Poon

    Citation: BMC Cancer 2017 17:126

    Published on:

  16. Content type: Research article

    Photodynamic therapy (PDT) has proven to be a promising alternative to current cancer treatments, especially if combined with conventional approaches. The technique is based on the administration of a non-toxi...

    Authors: Laura Marise de Freitas, Rodolfo Bortolozo Serafim, Juliana Ferreira de Sousa, Thaís Fernanda Moreira, Cláudia Tavares dos Santos, Amanda Martins Baviera, Valeria Valente, Christiane Pienna Soares and Carla Raquel Fontana

    Citation: BMC Cancer 2017 17:123

    Published on:

  17. Content type: Research article

    Glioblastoma Multiforme (GBM) is the most common and lethal form of primary brain tumor in adults. Following standard treatment of surgery, radiation and chemotherapy, patients are expected to survive 12–14 mo...

    Authors: Zachary C. Gersey, Gregor A. Rodriguez, Eric Barbarite, Anthony Sanchez, Winston M. Walters, Kelechi C. Ohaeto, Ricardo J. Komotar and Regina M. Graham

    Citation: BMC Cancer 2017 17:99

    Published on:

  18. Content type: Research article

    Advanced urothelial carcinomas represent a considerable clinical challenge as they are difficult to treat. Platinum-based combination regimens obtain response rates ranging from 40 to 70% in first-line therapy...

    Authors: Sergey A. Dyshlovoy, Ramin Madanchi, Jessica Hauschild, Katharina Otte, Winfried H. Alsdorf, Udo Schumacher, Vladimir I. Kalinin, Alexandra S. Silchenko, Sergey A. Avilov, Friedemann Honecker, Valentin A. Stonik, Carsten Bokemeyer and Gunhild von Amsberg

    Citation: BMC Cancer 2017 17:93

    Published on:

  19. Content type: Research article

    Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced dise...

    Authors: Martin McLaughlin, Holly E. Barker, Aadil A. Khan, Malin Pedersen, Magnus Dillon, David C. Mansfield, Radhika Patel, Joan N. Kyula, Shreerang A. Bhide, Kate L. Newbold, Christopher M. Nutting and Kevin J. Harrington

    Citation: BMC Cancer 2017 17:86

    Published on:

  20. Content type: Research article

    Osteosarcoma (OS) is the most common primary bone tumor in both humans and dogs and is the second leading cause of cancer related deaths in children and young adults. Limb sparing surgery along with chemothera...

    Authors: Sridhar Murahari, Aimee L. Jalkanen, Samuel K. Kulp, Ching-Shih Chen, Jaime F. Modiano, Cheryl A. London and William C. Kisseberth

    Citation: BMC Cancer 2017 17:67

    Published on:

Previous Page Page 2 of 19 Next Page